Skip to main content
An official website of the United States government

Pre-Cancer Atlas (PCA)

A tumor (yellow) is shown in the background. Components within the microenvironment are overlaid on the tumor, including a dendritic cell (pink), a T-cell (blue), a fibroblast (purple and pink), a natural killer cell (dark blue), a regulatory t cell (aqua), blood vessels (red), a macrophage cell (red with a yellow center), and a myeloid cell (green).

The Pre-cancer Atlas (PCA) Research Centers are part of the Human Tumor Atlas Network (HTAN). HTAN, an NCI-collaborative program, is constructing multi-dimensional atlases of the cellular, morphological, molecular, and spatial features of human cancers and their surrounding microenvironments over time.

The atlases being created by HTAN describe important changes during cancer progression, such as the transition of precancers to malignant tumors, the evolution of metastatic cancer, and the development of treatment resistance.

HTAN is supported by the NCI Division of Cancer Prevention (DCP), NCI Division of Biology (DCB), the NCI Division of Cancer Treatment and Diagnosis (DCTD), and the NCI Center for Strategic Science Initiatives (CSSI).

On This Page

  • All Heading 2s will automatically be pulled in to this list.
  • Do not edit the content on this template.

About Pre-Cancer Atlas

The Pre-cancer Atlas (PCA) Research Centers, along with the Human Tumor Atlas (HTA) Research Centers and a Data Coordinating Center (DCC), make up HTAN. Each PCA Research Center will create a 2D/3D precancer atlas of a pre-cancerous lesion, focusing on how it changes into cancer.

PCA Research Centers have three major tasks:

  • Collecting, processing, and labeling biospecimens.
  • Studying the molecular, cellular, and spatial details of the lesions.
  • Analyzing and modeling the data.

PCA Research Centers will collaborate with other components of HTAN to make the data and analytical tools available to the research community.

Grantee Details

PI Name Sort descending PI Organization Title Grant Number Program Official
Shah, Sohrab P

Sloan-Kettering Inst Can Research
United States

Exploiting markers of genomic instability in high-risk pre-invasive ovarian cancer 5R01CA281928-03 Christos Patriotis, Ph.D., M.Sc.
Shain, Alan Hunter

University Of California, San Francisco
United States

Pre-cancer atlas of skin cancer 4U01CA294536-02 Nicholas Hodges, Ph.D.
Shalon, Tidhar Dari

Envivo Bio Inc
United States

Development and clinical evaluation of the CapScan gastrointestinal sampling device for metabolomics monitoring 5R33CA260665-04 Amit Kumar, Ph.D.
Shelby, Rebecca A

Duke University
United States

Persistent Post-Mastectomy Pain: Randomized Clinical Trial of Targeted Pain Coping Skills Training (Targeted-PCST) with Mediational Analysis 5R01CA249959-05 Brennan Streck, Ph.D., RN, M.P.H.
Shelby, Rebecca A

Duke University
United States

Persistent Post-Mastectomy Pain: Randomized Clinical Trial of Targeted Pain Coping Skills Training (Targeted-PCST) with Mediational Analysis 5R01CA249959-05 Brennan Streck, Ph.D., RN, M.P.H.
Shelby, Rebecca A

Duke University
United States

Improving outcomes for women experiencing premature or early menopause after cancer: development and pilot testing of a novel intervention 1R21CA301298-01 Goli Samimi, Ph.D., M.P.H.
Shelby, Rebecca A

Duke University
United States

Improving outcomes for women experiencing premature or early menopause after cancer: development and pilot testing of a novel intervention 1R21CA301298-01 Goli Samimi, Ph.D., M.P.H.
Shiozawa, Yusuke

Wake Forest University Health Sciences
United States

Contribution of cutaneous neuro-immune interactions to chemotherapy-induced peripheral neuropathy 1R21CA297068-01 Rachel Altshuler, Ph.D.
Shiozawa, Yusuke

Wake Forest University Health Sciences
United States

Contribution of cutaneous neuro-immune interactions to chemotherapy-induced peripheral neuropathy 1R21CA297068-01 Rachel Altshuler, Ph.D.
Shirwan, Haval

University Of Missouri-Columbia
United States

Developing a novel agonist of CD137 for cancer immunoprevention 5UG3CA290305-02 Altaf Mohammed, Ph.D.
Shu, Xiao-Ou

Vanderbilt University Medical Center
United States

Use of Circulating MicroRNAs for Early Detection and Risk Assessment for Pancreatic Cancer 5R01CA227133-05 Matthew Young, Ph.D.
Shureiqi, Imad

University Of Michigan At Ann Arbor
United States

ALOX15 regulation of colon cancer invasiveness via PI3P-linoleic acid metabolism 5R01CA266223-04 Nancy J. Emenaker, Ph.D., RDN, LD, FAND
Siddique, Shahzad

Commonspirit Health Research Institute
United States

CIRI Oncology Research Alliance 3UG1CA189809-11S1 Vanessa A. White, M.P.H.
Siddique, Shahzad

Commonspirit Health Research Institute
United States

CIRI Oncology Research Alliance 3UG1CA189809-11S1 Vanessa A. White, M.P.H.
Sidransky, David

Johns Hopkins University
United States

Racial differences in Immunogenetic Tumorigenesis of Head and Neck Squamous Cell Carcinoma 5R01CA265975-04 Wendy Wang, Ph.D., M.Sc.